Tikva Allocell Pte. Ltd. has closed an $8 million Series A financing led by Kantharos Capital to complete IND-enabling work for TAVST01, its investigational off-the-shelf cell therapy targeting B7-H3-positive solid tumors. The Singapore biotechnology company plans to submit an Investigational New Drug application by the end of 2026 and, subject to regulatory clearance, begin a Phase 1 trial at sites in Singapore and the United States.
The financing moves TAVST01 closer to its first regulatory and clinical test, but it does not yet validate the programme’s central therapeutic hypothesis. Tikva Allocell remains a preclinical-stage company, and the published evidence supporting its platform comes from laboratory experiments, mouse studies and patient-derived xenograft models rather than treated patients. The significance of the Series A therefore lies in whether the company can convert an interesting persistence strategy into a reproducible clinical product, an accepted IND and eventually measurable human safety and pharmacokinetic data.
What will Tikva Allocell’s $8 million Series A financing actually allow the company to prove?
Tikva Allocell said the proceeds will support the remaining IND-enabling activities for TAVST01 and its planned year-end submission. These activities typically extend beyond additional efficacy experiments and include toxicology, manufacturing process qualification, analytical method development, product-release specifications, stability testing and preparation of the clinical protocol and regulatory documentation.
The company did not disclose its valuation, the size of any previous financing, the ownership acquired by Kantharos Capital or how long the new capital is expected to fund operations. It also did not say whether the $8 million will finance the start of the proposed Phase 1 study or primarily carry TAVST01 through IND submission and regulatory review. That distinction matters because early clinical development of engineered cell therapies requires specialist manufacturing, cryogenic logistics, intensive safety monitoring and clinical sites capable of managing cell therapy complications.
For a company founded in 2023, the financing nevertheless represents a meaningful transition from platform creation to regulatory execution. Tikva Allocell has already licensed virus-specific T-cell technologies from Baylor College of Medicine and established a research collaboration in Singapore with the Agency for Science, Technology and Research’s Institute of Molecular and Cell Biology. The Series A now puts a defined deadline against that scientific foundation: management must deliver an IND-quality product package rather than another preclinical proof of concept.
How is TAVST01 designed to overcome immune rejection that limits donor-derived CAR-T cells?
TAVST01 combines three central components. It uses Epstein-Barr virus-specific T cells obtained from donors, equips those cells with a chimeric antigen receptor targeting B7-H3 and incorporates an engineered form of SerpinB9 intended to protect the infused cells from immune-mediated destruction.
The choice of Epstein-Barr virus-specific T cells is intended to address graft-versus-host disease and persistence challenges associated with conventional donor T cells. Virus-specific T cells have a more restricted T-cell receptor repertoire because they are selected for their ability to recognise viral antigens. Tikva Allocell’s scientific rationale is that this narrower activity may reduce the risk that the donor cells attack healthy recipient tissues while retaining a cell population capable of expansion and persistence.
The second component directs the cells against B7-H3, also known as CD276, a surface protein expressed at elevated levels across multiple solid tumor types. Tikva Allocell has identified lung, breast, prostate, pancreatic and pediatric cancers among the possible areas of development, although the eventual Phase 1 protocol and initial tumor cohorts have not been disclosed. Calling TAVST01 tumor agnostic at this stage would be premature because clinical activity may vary substantially with antigen density, tumor location, disease burden and the immunological characteristics of each cancer.
The SerpinB9 engineering provides the platform’s most differentiated element. Granzyme B is one of the mechanisms used by immune cells to destroy target cells, including donor-derived therapeutic cells recognised as foreign. Tikva Allocell’s engineered SB9(CAS) protein is designed to inhibit this cell-death pathway, allowing TAVST01 to resist host immune rejection and activation-induced cell death caused by repeated exposure to tumor antigens.
What does the published preclinical evidence establish about TAVST01 and its underlying platform?
A 2024 study in Cancer Research Communications evaluated B7-H3-targeting CAR-engineered Epstein-Barr virus-specific T cells in laboratory and animal models. The cells demonstrated activity against multiple B7-H3-positive tumor cell lines and reduced tumor growth in mouse and patient-derived xenograft models. The investigators also reported activity against B7-H3-expressing myeloid-derived suppressor cells, suggesting a possible mechanism for modifying parts of the immunosuppressive tumor microenvironment.
The study provides a credible biological basis for advancing the programme, but its limitations are substantial. Xenograft and humanised mouse models cannot fully reproduce the immune rejection, tumor heterogeneity, trafficking barriers and treatment-related toxicities that appear in patients. The study also found that the engineered cells targeted monocytes and certain stimulated or more mature hematopoietic progenitor populations because those cells expressed B7-H3. That observation does not establish that clinically significant toxicity will occur, but it makes monitoring of myeloid cells, blood counts, inflammatory markers and potential on-target effects an important part of first-in-human development.
A separate Cancer Immunology Research paper examined the engineered SerpinB9 strategy in allogeneic CAR-T cells. SB9(CAS) overexpression reduced immune-mediated rejection and activation-induced cell death while improving cellular persistence and antitumor activity in laboratory and animal experiments. Researchers reported that they did not observe autonomous cell growth and that the engineered cells remained responsive to an inducible suicide mechanism, offering preliminary reassurance that protection from cell death did not make the cells completely uncontrollable.
Those results remain preclinical. Human immune systems may eliminate the cells through pathways not sufficiently blocked by SerpinB9, while excessive protection against normal cell-death signals could potentially introduce different safety or persistence concerns. Phase 1 testing will therefore need to measure not only whether TAVST01 survives longer than other donor-derived products, but whether that survival remains controllable and translates into tumor exposure without unacceptable toxicity.
Why does recent B7-H3 CAR-T clinical evidence make persistence the decisive question for TAVST01?
Tikva Allocell is entering a field in which B7-H3 has already attracted multiple autologous and allogeneic cell therapy programmes. The target’s broad expression makes it commercially appealing, but early clinical experience also illustrates why target selection alone is not enough to overcome the barriers facing solid tumor CAR-T therapies.
A Phase 1 study published in May 2026 evaluated UTAA06, an allogeneic B7-H3-targeted CAR Vδ1 T-cell therapy, in ten patients with advanced solid tumors. The study reported no graft-versus-host disease, two transient grade 1 cytokine release syndrome events and one dose-limiting grade 3 pneumonitis. However, no objective responses were recorded under standard RECIST criteria, and the investigators linked the limited activity to short cellular persistence associated with host-versus-graft rejection.
That trial cannot be used to predict how TAVST01 will perform because the two products use different cell types, engineering strategies, manufacturing processes, doses and patient populations. It does, however, validate the importance of the problem Tikva Allocell is attempting to solve. A donor-derived B7-H3 CAR-T product can appear manageable from a graft-versus-host disease perspective and still fail to remain in the patient long enough to generate meaningful tumor responses.
For TAVST01, early blood and tumor pharmacokinetic measurements may consequently be as informative as initial response rates. Investigators will need to determine whether the cells expand after infusion, how long they remain detectable, whether repeat dosing increases exposure and whether persistence differs among patients with varying levels of immune competence or B7-H3 expression.
Could lymphodepletion-free administration and repeat dosing change the economics of solid tumor CAR-T?
Tikva Allocell said TAVST01’s preclinical profile may support administration without lymphodepleting chemotherapy, repeat dosing and combination strategies. These remain development possibilities rather than confirmed features of the future clinical programme.
Avoiding lymphodepletion would be strategically important. Most CAR-T protocols use chemotherapy before infusion to reduce competing immune cells and create biological space for the therapeutic cells to expand. That conditioning can contribute to cytopenias, infections and treatment complexity. A donor-derived therapy able to persist without aggressive lymphodepletion could potentially be administered to a broader range of patients and more easily incorporated into combination regimens.
The trade-off is that an intact immune system may reject donor cells more quickly. TAVST01’s SerpinB9 engineering is designed to resist one important killing mechanism, but it may not neutralise every pathway involved in host-versus-graft rejection. The first trial may therefore need to test different conditioning approaches or begin with conventional lymphodepletion before attempting a chemotherapy-free regimen.
Repeat dosing could also distinguish an off-the-shelf product from autologous CAR-T therapy. Donor-derived cells can theoretically be manufactured in batches, stored and supplied when needed, avoiding the patient-specific collection and manufacturing process required for autologous products. That could shorten treatment timelines and allow additional infusions when cell levels decline.
Off-the-shelf availability does not automatically create low-cost treatment, however. TAVST01 still requires donor screening, EBV-specific cell selection or expansion, CAR introduction, SerpinB9 engineering, potency testing, sterility testing, cryopreservation and controlled distribution. Commercial viability will depend on how many consistent doses Tikva Allocell can produce from each manufacturing run and whether the final product retains potency after storage and transport.
What must Tikva Allocell demonstrate before TAVST01 can become more than a promising platform?
The IND submission planned for the end of 2026 is the immediate milestone, but the quality of the subsequent Phase 1 trial will determine whether Tikva Allocell has created a differentiated clinical asset. The company will need to define an appropriate B7-H3 biomarker threshold, select tumor cohorts where antigen expression and unmet need justify cell therapy, establish a rational starting dose and explain whether patients will receive lymphodepletion.
Safety monitoring will need to cover cytokine release syndrome, neurological events, graft-versus-host disease, cytopenias, infections, organ toxicities and potential effects on B7-H3-expressing normal immune or progenitor cells. Pharmacokinetic testing should establish expansion, persistence, trafficking and the effect of any repeat infusions. Tumor biopsies, where feasible, could help determine whether the cells reach the tumor and remain functional inside an immunosuppressive microenvironment.
The breadth of B7-H3 expression creates several potential development paths, but it also raises the danger of an overly broad early programme. A focused initial population with measurable antigen expression and a realistic opportunity to detect biological activity may provide more useful evidence than enrolling a highly heterogeneous collection of advanced cancers.
Tikva Allocell must also show that SerpinB9 protection produces a meaningful difference in humans. Persistence that lasts several days longer without tumor penetration would have limited therapeutic value. Longer persistence accompanied by uncontrolled inflammation would create a different problem. The clinically relevant outcome is sustained, controllable exposure that produces tumor activity at a tolerable dose.
The $8 million Series A gives Tikva Allocell the capital to approach that question, not the answer itself. Successful IND clearance would confirm that regulators consider the manufacturing, toxicology and clinical package sufficient to begin testing. The more consequential test will come after dosing, when human data show whether engineered EBV-specific T cells can withstand immune rejection without losing the safety advantages expected from an off-the-shelf platform.
TAVST01 will become strategically important if its first clinical results demonstrate reproducible persistence, manageable immune toxicity and evidence that the cells can reach B7-H3-positive tumors. Until then, the financing should be viewed as a carefully targeted bridge from credible preclinical science to a demanding first-in-human experiment.
